Detalhe da pesquisa
1.
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Br J Cancer
; 126(3): 430-439, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046520
2.
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Prostate
; 78(8): 623-630, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29520847
3.
Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Clin Genitourin Cancer
; 20(5): 399-403, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680530
4.
Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
Urol Oncol
; 36(6): 309.e7-309.e14, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29551548
5.
Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
PLoS One
; 9(3): e93162, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24664420
6.
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
Clin Cancer Res
; 20(21): 5456-67, 2014 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24893628
7.
Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.
PLoS One
; 8(2): e56912, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23457640